Tempest reports Q3 net loss $3.5M, cash $7.5M; continues strategic alternatives process

Tempest Therapeutics, Inc.

2025-Q3 EPS reported -$5.71

Cash and equivalents $7.5M at Sept 30, 2025, down from $30.3M at Dec 31, 2024.
Net loss Q3 2025: $3.5M ($0.79/share) vs $10.6M ($5.32/share) in Q3 2024.
R&D expenses fell to $0.6M from $7.6M due to reprioritizing toward strategic alternatives.
Company continues strategic alternatives process to maximize stockholder value.
Expects start of TPST-1495 Phase 2 in collaboration with NCI and Cancer Prevention Clinical Trials Network.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.